Skip to main content
Clinical Trials/NCT01169311
NCT01169311
Completed
Not Applicable

A Prospective, Multi-Center Investigation Of The Safety And Performance Of The Covidien EEA™ Hemorrhoid And Prolapse Stapling Set With DST Series™ Technology Im A Hemorrhoidopexy Procedure

Medtronic - MITG1 site in 1 country27 target enrollmentJuly 2010
ConditionsHemorrhoid

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Hemorrhoid
Sponsor
Medtronic - MITG
Enrollment
27
Locations
1
Primary Endpoint
Uneventful Creation of a Functional Staple Line at First Firing of Device
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

Trial Objectives

The primary objectives of this clinical trial are to estimate the Covidien EEA™ Hemorrhoid and Prolapse Stapling Set:

overall performance defined by the successful creation of a normal staple line safety as measured by the 30 day incidence of adverse events.

Registry
clinicaltrials.gov
Start Date
July 2010
End Date
July 2011
Last Updated
11 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Able to understand and sign Informed Consent Form
  • The participant must be 18-80 years of age.
  • The participant has (symptomatic) Grade 2-4 Hemorrhoids and is eligible for stapled hemorrhoidopexy.

Exclusion Criteria

  • The procedure is needed as revision hemorrhoid surgery.
  • The participant is pregnant.
  • The participant has an active or a history of infection requiring antibiotics at the intended operative site within thirty (30) days prior to the planned surgery date.
  • The participant is unable or unwilling to comply with the study requirements, follow-up schedule.
  • The participant has a history of drug or alcohol abuse.
  • The participant has a history of venous thrombosis or pulmonary embolism.
  • The participant has a history of coagulopathy.
  • The participant is taking aspirin, anti-coagulation and/or anti platelet therapies (e.g.: Warfarin, Levonox) within the last 7 days prior to the planned surgery date
  • The participant has a history of fecal incontinence.
  • The participant has co-morbidities which, in the opinion of the investigator, will not be appropriate for the study.

Outcomes

Primary Outcomes

Uneventful Creation of a Functional Staple Line at First Firing of Device

Time Frame: about 20 minutes for procedure

Successful creation of staple line at first firing of device during hemorrhoidopexy

Secondary Outcomes

  • Intra-Operative Bleeding Requiring Intervention(Day 0 - time of surgery)
  • Post Operative Pain(baseline, 30 days post op)
  • Time to Return to Normal Activity(30 days post op)
  • Length of Stay(Day 0, time of discharge minus time of admission)
  • OR Time(Day 0 - Time of stop minus time of start)
  • Quality of Life, Physical Component(baseline, 30 days post op)
  • Incidence of Stapler Malfunction or Misfires(about 20 minutes for procedure)
  • Quality of Life, Mental Component(Baseline, 30 days post op)

Study Sites (1)

Loading locations...

Similar Trials